Personalized medicine and cancer supportive care: Appropriate use of colony-stimulating factor support of chemotherapy

Journal of the National Cancer Institute

Volumn 103, Issue 12, 2011, Pages 910-913

  Kuderer, Nicole M ^a   Lyman, Gary H ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMORBIDITY; EDITORIAL; FEBRILE NEUTROPENIA; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; MULTIPLE CYCLE TREATMENT; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLONY-STIMULATING FACTORS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; FEVER; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION; UNITED STATES;

EID: 79959763969     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr195     Document Type: Editorial

References (40)

1. Lyman GH , Michels SL , Reynolds MW , Barron R , Tomic KS , Yu J . Risk of mortality in patients with cancer who experience febrile neutropenia . Cancer. 2010 ; 116 ( 23 ): 5555-5563 .
2. Kuderer NM , Dale DC , Crawford J , Cosler LE , Lyman GH . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients . Cancer. 2006 ; 106 ( 10 ): 2258-2266 . (Pubitemid 43673249)
3. Carratala J , Roson B , Fernandez-Sevilla A , Alcaide F , Gudiol F . Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome . Arch Intern Med. 1998 ; 158 ( 8 ): 868-872 . (Pubitemid 28183641)
4. Darmon M , Azoulay E , Alberti C , et al . Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients . Intensive Care Med. 2002 ; 28 ( 12 ): 1775-1780 . (Pubitemid 35435480)
5. Elting LS , Rubenstein EB , Rolston KV , Bodey GP . Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials . Clin Infect Dis. 1997 ; 25 ( 2 ): 247-259 . (Pubitemid 27364722)
6. Gonzalez-Barca E , Fernandez-Sevilla A , Carratala J , et al . Prognostic factors infl uencing mortality in cancer patients with neutropenia and bacteremia . Eur J Clin Microbiol Infect Dis. 1999 ; 18 ( 8 ): 539-544 . (Pubitemid 29531221)
7. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003 ; 98 ( 11 ): 2402-2409 . (Pubitemid 37466655)
8. Crawford J , Dale DC , Kuderer NM , et al . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice . J Natl Compr Canc Netw. 2008 ; 6 ( 2 ): 109-118 . (Pubitemid 351340522)
9. Chouaid C , Bassinet L , Fuhrman C , Monnet I , Housset B . Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model . J Clin Oncol. 1998 ; 16 ( 8 ): 2700-2707 . (Pubitemid 28363033)
10. Kuderer NM , Dale DC , Crawford J , Lyman GH . Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review . J Clin Oncol. 2007 ; 25 ( 21 ): 3158-3167 . (Pubitemid 47218066)
11. Aapro MS , Bohlius J , Cameron DA , et al . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours . Eur J Cancer. 2011 ; 47 ( 1 ): 8-32 .
12. Lyman GH , Dale DC , Wolff DA , et al . Acute myeloid leukemia or myelo-dysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review . J Clin Oncol. 2010 ; 28 ( 17 ): 2914-2924 .
13. Smith TJ , Khatcheressian J , Lyman GH , et al . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline . J Clin Oncol. 2006 ; 24 ( 19 ): 3187-3205 . (Pubitemid 46638957)
14. Crawford J , Armitage J , Balducci L , et al . Myeloid growth factors . J Natl Compr Canc Netw. 2009 ; 7 ( 1 ): 64-83 .
15. Freifeld AG , Bow EJ , Sepkowitz KA , et al . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America . Clin Infect Dis. 2011 ; 52 ( 4 ): 427-431 .
16. Lyman GH . A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia [published online ahead of print October 29, 2010] . Curr Opin Hematol . 2010 .
17. Lyman GH , Kleiner JM . Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy . Cancer Treat Res. 2011 ; 157 : 145-165 .
18. Dale DC , McCarter GC , Crawford J , Lyman GH . Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials . J Natl Compr Canc Netw. 2003 ; 1 ( 3 ): 440-454 .
19. Talcott JA , Siegel RD , Finberg R , Goldman L . Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule . J Clin Oncol. 1992 ; 10 ( 2 ): 316-322 .
20. Klastersky J , Paesmans M , Rubenstein EB , et al . The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients . J Clin Oncol. 2000 ; 18 ( 16 ): 3038-3051 . (Pubitemid 30644129)
21. Lyman GH , Kuderer NM , Crawford J , et al . Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy . Cancer. 2011 ; 117 ( 9 ): 1917 - 1927 .
22. Lyman GH , Lyman CH , Agboola O . Risk models for predicting chemotherapy-induced neutropenia . Oncologist. 2005 ; 10 ( 6 ): 427-437 . (Pubitemid 40993570)
23. Potosky AL , Malin JL , Kim B , et al . Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes . J Natl Cancer Inst. 2011 ; 103 ( 12 ): 979-982 .
24. Lyman GH , Dale DC , Crawford J . Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices . J Clin Oncol. 2003 ; 21 ( 24 ): 4524-4531 . (Pubitemid 46594022)
25. Lyman GH , Dale DC , Friedberg J , Crawford J , Fisher RI . Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin ' s lymphoma: a nationwide study . J Clin Oncol. 2004 ; 22 ( 21 ): 4302-4311 . (Pubitemid 41185151)
26. Lyman GH . Impact of chemotherapy dose intensity on cancer patient outcomes . J Natl Compr Canc Netw. 2009 ; 7 ( 1 ): 99-108 .
27. Chrischilles EA , Pendergast JF , Kahn KL , et al . Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer . J Clin Oncol. 2010 ; 28 ( 4 ): 620-627 .
28. Ayanian JZ , Chrischilles EA , Fletcher RH , et al . Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium . J Clin Oncol. 2004 ; 22 ( 15 ): 2992-2996 .
29. Hassett MJ , O'Malley AJ , Pakes JR , Newhouse JP , Earle CC . Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer . J Natl Cancer Inst. 2006 ; 98 ( 16 ): 1108-1117 . (Pubitemid 44288785)
30. Hurria A , Brogan K , Panageas KS , et al . Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy . Drugs Aging. 2005 ; 22 ( 8 ): 709-715 . (Pubitemid 41138982)
31. Bennett CL , Smith TJ , Weeks JC , et al . Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology . J Clin Oncol. 1996 ; 14 ( 9 ): 2511-2520 . (Pubitemid 26300118)
32. Griggs JJ , Sorbero ME , Lyman GH . Undertreatment of obese women receiving breast cancer chemotherapy . Arch Intern Med. 2005 ; 165 ( 11 ): 1267-1273 . (Pubitemid 40989591)
33. Shayne M , Crawford J , Dale DC , Culakova E , Lyman GH . Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy . Breast Cancer Res Treat. 2006 ; 100 ( 3 ): 255-262 . (Pubitemid 44707919)
34. Griggs JJ , Culakova E , Sorbero ME , et al . Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens . J Clin Oncol. 2007 ; 25 ( 18 ): 2522-2527 . (Pubitemid 47041224)
35. Griggs JJ , Culakova E , Sorbero ME , et al . Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy . J Clin Oncol. 2007 ; 25 ( 3 ): 277-284 . (Pubitemid 350010638)
36. Rajan SS , Lyman GH , Carpenter WR , Stearns SC . Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer . Breast Cancer Res Treat . 2011 ; 127 ( 2 ): 511-520 .
37. Lyman GH , Kuderer N , Greene J , Balducci L . The economics of febrile neutropenia: implications for the use of colony-stimulating factors . Eur J Cancer. 1998 ; 34 ( 12 ): 1857-1864 . (Pubitemid 28535432)
38. Eldar-Lissai A , Cosler LE , Culakova E , Lyman GH . Economic analysis of prophylactic pegfi lgrastim in adult cancer patients receiving chemotherapy . Value Health. 2008 ; 11 ( 2 ): 172-179 . (Pubitemid 351473616)
39. Ramsey SD , Liu Z , Boer R , et al . Cost-effectiveness of primary versus secondary prophylaxis with pegfi lgrastim in women with early-stage breast cancer receiving chemotherapy . Value Health. 2009 ; 12 ( 2 ): 217-225 .
40. Eddy DM , Adler J , Patterson B , Lucas C , Smith KA , Morris M . Individualized guidelines: the potential for increasing quality and reducing costs . Ann Intern Med. 2011 ; 154 ( 9 ): 627-634 .